~
Ovarian cancer is the fifth leading cause of cancer death among American women. In 2014, it killed more than 14,000 women. Given the rate of diagnosis, there are more women in the pipeline for next year and the next and the one after that. If you are not fighting this disease, you probably know someone who is.
 
That’s yesterday’s news. Today’s news is that the Federal Drug Administration is willing to support continued research into a treatment option that is based on Dronabinol, a cannabinoid, which is one of the many non-THC derivatives of the cannabis plant. The prospects for the future include not only better treatment options for those diagnosed with ovarian cancer, but more research into the largely untouched medical potential of cannabis.
 
Ovarian Cancer
 
It is a hard disease to detect and treat. The symptoms of the early stages, when it is most curable, are subtle and many women dismiss them. It is resistant to current treatments, particularly after the first drug round. Much depends on the stage at which this kind of cancer is diagnosed, but the overall five-year survival rate is less than half.
 
So, message number one for all you ladies out there, especially if you are white and over 60, is to get yourselves into the doctor’s office for a checkup.
 
Treatment Options and Issues
 
When the diagnosis is ovarian cancer, doctors often recommend aggressive measures, including two or more different types of treatments. The options include surgery, chemotherapy, hormone therapy, targeted therapy and radiation therapy. Each can have life-threatening complications.
 
Insys Therapeutic Inc.’s Liposomal Encapsulated Paclitaxel, a drug which contains Dronabinol, may soon be part of the package of options. In drug trials it has reportedly been effective in the treatment of the nausea and vomiting associated with cancer chemotherapy as well as anorexia associated with weight loss in patients with AIDS.
 
What’s New?
 
Cannabis as medicine is not new; the recognition that it may be helpful in treating nausea is not new, but the investment incentives that come with FDA greenlighting are new. LEP’s special status under The Orphan Drug Act, qualifies Insys for various development incentives, including tax credits for qualified clinical testing and a seven-year period of U.S. marketing exclusivity upon approval. These incentives may support LEP’s development.
 
Broader Implications
 
Additional treatment options for patients undergoing chemotherapy or who are otherwise fighting weight loss are important. Development incentives for drug companies should expand those options. That is good for drug companies.
 
The larger investment picture, however, involves the recognition that cannabis and cannabis derivatives may have acceptable medical uses that are inconsistent with its classification as a Schedule I drug. Every recognized medical use helps to build a stronger case for descheduling. Were cannabis removed from the Controlled Substance Act’s schedules, research into other medical uses would be easier to fund. Investors would be more willing to support research. The virtuous circle of growth and investment could begin to function.
 
Anne Wallace ~ MJI News ~ January 29, 2015
 
~
April 03, 2020

Trans-Atlantic hemp trade hit by uncertainties -…

Supply-chain disruptions and delivery delays have become the new normal for hemp and other agricultural commodities as governments keep their…
April 03, 2020

Older adults and medical marijuana: Reduced stigma…

As a primary care doctor who has incorporated medical cannabis into his practice, it is notable how many silver-haired patients…
April 03, 2020

Marijuana firms shift to virtual 4/20 celebrations…

Cannabis companies that were planning to host elaborate monthlong celebrations around 4/20 have been forced to change plans and are…
April 02, 2020

Illinois cannabis sales hit nearly $36 million…

According to the Illinois Department of Financial and Professional Regulation, adult-use cannabis sales hit $35,902,543.22 in March.
April 02, 2020

USDA Approves Hemp Plans For South Carolina…

The U.S. Department of Agriculture (USDA) announced on Tuesday that is approved hemp regulatory plans for two additional states and…
April 02, 2020

Should COVID-19 Allow Medical Patients To Grow…

While some medical marijuana states allow home cultivation, others do not, potentially harming lives during the coronavirus outbreak.
April 02, 2020

Oklahoma Lawmakers Consider Recreational Marijuana To Fill…

COVID-19 is having a multi-million dollar impact on the state budget. One lawmaker said the solution might be to legalize…
April 01, 2020

Cannabis Scientists Are Chasing the Perfect High…

Chemists at some of the biggest legal-weed companies are after an elusive prize: a predictable, reliable product.
April 01, 2020

Hemp farming approved to begin in Georgia…

Hemp farming has finally gotten the green light to begin in Georgia, bringing a new crop that will sprout this…
April 01, 2020

Nevada marijuana deliveries are skyrocketing. Is this…

Much like the grocery stores trying to fill orders for rice and potatoes, cannabis retailers cannot fill marijuana delivery orders…
April 01, 2020

Study finds CBG useful in killing MRSA,…

Researchers at McMaster University in Canada recently published a paper describing how cannabigerol, the common cannabinoid known as CBG, killed…